Quality of life: not reported · women with endometriosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Restriction of daily life activities ‐ not reported · women with endometriosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Absence from work or school: not reported · women with endometriosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women requiring more invasive treatment: not reported · women with endometriosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Requirement for additional medication · women with endometriosis
It is very uncertain whether NSAID changes requirements for additional medication compared with placebo (very low certainty).
1 finding from 1 review
Participant satisfaction with treatment: not reported · women with endometriosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence of dysmenorrhoea · women with symptomatic endometriosis
Mifepristone probably leads to lower prevalence of dysmenorrhoea compared with placebo (moderate certainty).
1 finding from 1 review
Side effects ‐ hot flushes · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes side effects: hot flushes compared with danazol (very low certainty).
1 finding from 1 review
Adverse effects: acne · women with symptomatic endometriosis
Gestrinone showed no clear difference in side effects: acne compared with danazol (low certainty).
1 finding from 1 review
Dysmenorrhoea, verbal rating scale · women with symptomatic endometriosis
1 finding from 1 review
Painful intercourse ‐ Dyspareunia · women with symptomatic endometriosis
1 finding from 1 review
Amenorrhoea · women with symptomatic endometriosis
Gestrinone may leads to lower amenorrhoea compared with leuprolin (low certainty).
1 finding from 1 review
Percentage days bleeding or spotting (questionnaire) · women with symptomatic endometriosis
Gestrinone may leads to higher spotting or bleeding compared with leuprolin (low certainty).
1 finding from 1 review
Side effects ‐ hot flushes · women with symptomatic endometriosis
Gestrinone may leads to lower side effects: hot flushes compared with leuprolin (low certainty).
1 finding from 1 review
Prevalence of dyspareunia · women with symptomatic endometriosis
Mifepristone may leads to lower prevalence of dyspareunia compared with placebo (low certainty).
1 finding from 1 review
Side effects ‐ amenorrhoea · women with symptomatic endometriosis
Mifepristone leads to higher side effects: amenorrhoea compared with placebo (high certainty).
1 finding from 1 review
Side effects ‐ hot flushes · women with symptomatic endometriosis
Mifepristone leads to higher side effects: hot flushes compared with placebo (high certainty).
1 finding from 1 review
Pelvic pain · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes pelvic pain: none or mild compared with danazol (very low certainty).
1 finding from 1 review
Dysmenorrhoea: none or mild · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes dysmenorrhoea: none or mild compared with danazol (very low certainty).
1 finding from 1 review
Dyspareunia: none or mild · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes dyspareunia: none or mild compared with danazol (very low certainty).
1 finding from 1 review